[Rheumatoid arthritis].
Kameda
Hideto
H
Second Department of Internal Medicine, Saitama Medical Center.
Takeuchi
Tsutomu
T
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D001323:Autoantibodies / Q000097:blood; D015551:Autoimmunity; D015415:Biomarkers / Q000097:blood; D000068800:Etanercept; D005956:Glucose-6-Phosphate Isomerase / Q000276:immunology; D006684:HLA-DR Antigens; D059811:HLA-DRB1 Chains; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D019278:Matrix Metalloproteinase 3 / Q000097:blood; D010456:Peptides, Cyclic / Q000276:immunology; D011379:Prognosis; D011505:Protein-Tyrosine Kinases; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D000069283:Rituximab; D012720:Severity of Illness Index; D051746:ZAP-70 Protein-Tyrosine Kinase
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D001323:Autoantibodies; D015415:Biomarkers; D006684:HLA-DR Antigens; D059811:HLA-DRB1 Chains; D007074:Immunoglobulin G; D010456:Peptides, Cyclic; D018124:Receptors, Tumor Necrosis Factor; C487763:cyclic citrullinated peptide; D000069283:Rituximab; D000069285:Infliximab; D011505:Protein-Tyrosine Kinases; D051746:ZAP-70 Protein-Tyrosine Kinase; C497261:ZAP70 protein, human; D019278:Matrix Metalloproteinase 3; D005956:Glucose-6-Phosphate Isomerase; D000068800:Etanercept